Visum Pharm

Visum Pharmaceutical is a China-based pharmaceutical company that specializes in the development, manufacturing, and commercialization of high-barrier generic drugs and innovative small molecule therapeutics. The company focuses primarily on therapeutic areas such as the central nervous system (CNS), cardiovascular diseases, and oncology. Visum is recognized for its high-standard GMP manufacturing facilities and has successfully obtained multiple Abbreviated New Drug Application (ANDA) approvals from the US FDA, facilitating its entry into international markets. In November 2021, the company was acquired by Grand Pharmaceutical Group, which integrated Visum's R&D and production capabilities to strengthen its own CNS and high-end generic portfolio. Visum continues to operate as a key subsidiary, leveraging its expertise in complex formulations and international regulatory compliance.